GLUD1 and lung cancer: Anoikis resistance was reported in LKB1-deficient lung cancer with an elevated glutamate dehydrogenase 1 (GDH1) that is associated with an increased α-KG, leading to CamKK2-mediated AMPK activation and the repression of mTOR activity (72).